Uricase-Based Gout Drug Meets Endpoints in Phase 3 Trials :

Two phase 3 trials of the once-monthly SEL-212 in refractory gout achieved and maintained serum uric acid

Related Keywords

Washington , United States , Russia , Dallas , Texas , Milan , Lombardia , Italy , China , Sweden , Georgia , University Of Texas Southwestern Medical Center , Ukraine , Serbia , Swedish , Roy Fleischmann , Selecta Biosciences Imm , Herbert Sb Baraf , Biovitrum Sobi , European Congress , George Washington University , Metroplex Clinical Research Center , Drug Administration , Selecta Biosciences , Swedish Orphan Biovitrum , Texas Southwestern Medical Center , Gout , Refractory , Immune Tolerance , Arthritis , Oint Inflammation , Body Mass Index Bmi , Clinical Research , Clinical Trials , Linical Studies , Europe , European , Prophylaxis , Quality Of Life , Pol , Ealth Related Quality Of Life , Rqol , Stomatitis , Tolerance , Xanthines , Anaphylaxis , Biologic Therapy , Dentistry , Healthcare And Medical ,